<DOC>
	<DOC>NCT00576758</DOC>
	<brief_summary>This study will investigate the efficacy of weekly intravenous obinutuzumab [GA101 (RO5072759)] monotherapy, in patients with relapsed CD20+ indolent Non-Hodgkin's Lymphoma. Patients will be randomized to receive either GA101 or rituximab, given as four weekly infusions. At the conclusion of the initial trial patients may be eligible to continue therapy up to 24 months. The anticipated time on study treatment is 3- 24 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>GAUSS: A Study of Obinutuzumab (RO5072759) in Patients With Indolent Non-Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patients, &gt;=18 years of age relapsed CD20+ indolent Bcell nonHodgkin's lymphoma documented history of response of &gt;/= 6 months duration from last rituximabcontaining regimen clinical indication for treatment as determined by the investigator Eastern Cooperative Oncology Group (ECOG) performance status 02 prior use of any investigational monoclonal antibody within 6 months of study start prior use of any anticancer vaccine prior use of rituximab within 8 weeks of study entry radioimmunotherapy within 3 months prior to study entry Central Nervous System (CNS) lymphoma or evidence of transformation to highgrade or diffuse large Bcell lymphoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>